Home   »  TRADE TOPICS  »  Prescription Drugs  »  Trans Pacific Partnership

Trans Pacific Partnership

The TPP is a plurilateral trade agreement under negotiation by the U.S., Australia, Brunei, Chile, New Zealand, Peru, Singapore, and Vietnam. State leaders have warned trade officials that the inclusion of pharmaceutical provisions could limit Medicaid's ability to negotiate drug discounts.

General Content
Letter to President Obama from VT Governor Peter Shumlin on Pharmaceuticals and the Trans Pacific Partnership
June 1st, 2011
Gov. Shumlim warns that the pharmaceutical provisions sought by the pharmaceutical industry and 28 Senators will threaten state and local programs that rely on drug discounts.
Letter from ME State Rep. Sharon Treat and the Forum on Democracy and Trade to Rep. Waxman
May 3rd, 2011
This letter warns that the inclusion of a pharmaceuticals chapter in the Trans Pacific Partnership based on Chapter 5 of the Korea FTA threaten drug discounts for Medicaid, 340B, and Medicare Part B.
National Legislative Association on Prescription Drug Prices Resolution Opposing the Inclusion of a Pharmaceuticals Chapter in the Trans Pacific Partnership
January 24th, 2011
Resolution from an organization of state legislators warning trade officials to avoid the inclusion of pharmaceutical pricing provisions in the Trans Pacific Partnership. Such provisions were included in the bilateral agreements with Australia and Korea, and they threaten state and local programs that negotiate discounts from pharmaceutical companies for programs that serve the poor.
Letter from Five State Legislators to U.S. Trade Representative Ron Kirk
September 16th, 2010
ME Sen. Peggy Rotundo, ME Rep. Sharon Anglin Treat, VT Rep. Ginny Lyons, VT Rep. Kathleen Keenan, and NH Rep. Charles Reed have asked Ambassador Kirk to ensure that the TPP will not include provisions that limit the negotiation of drug prices.

Forum Analysis
Shape of U.S. TPP Pharmaceuticals Chapter Emerges
Commentary by AU Professor Sean Flynn describing the semi-leaked U.S. draft of a pharmaceuticals Chapter for the TPP.
State and Consumer Opposition to Trade Agreement Restrictions on Pharmaceutical Reimbursement and Pricing Programs
State officials and consumer organizations are opposed to the pharmaceutical industry agenda to insert new international trade law restrictions on the operation of government pharmaceutical reimbursement programs and other measures that restrain the excessive prices of brand name medicines.
Trans-Pacific Partnership & U.S. State Efforts to Control Drug Prices
U.S. trade policy seeks to limit the systems of evidence-based pricing used by foreign countries to control pharmaceutical costs. However, U.S. state governments use the same types of strategies to control costs for Medicaid and other programs that purchase drugs. Negotiated discounts lead to large cost savings, which states rely upon to continue to serve low-income Americans.

Unless otherwise expressly stated, all original material of whatever nature created by the Forum on Democracy & Trade website is licensed under a Creative Commons License. Privacy Statement | Sitemap